🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Are you a third year fellow? Or in your last year of training? We are starting a new series about finding that first job out of training. Part # 1 You may see some cameos in subsequent videos 😎 OncLive.com Oncology Brothers Hem-Onc Fellows Network #LatinasInMedicine #FlorezLab Sumanta K. Pal, MD, FASCO

I'm pleased to launch a new series, "Science Matters." We’ll explore why science matters, and which scientific 'matters' are key to translating cancer breakthroughs into better care for patients everywhere. I hope you enjoy the first installment! connection.asco.org/do/science-mat…

The #SATEENtrial led by Dana-Farber’s Breast Oncology Center is a multi-center, single-arm phase II trial to evaluate the safety and effectiveness of #SacituzumabGovitecan with trastuzumab for HER2+ #MetastaticBreastCancer.​ For more information call 877-338-7425 or visit:​ dana-farber.org/clinical-trial…

🎉 As I celebrate my birthday month, I’m raising $$ for METAvivor the only U.S. nonprofit that awards MBC research grants that are both patient & peer-reviewed. With federal research dollars shrinking, your support is more critical than ever. TYIA donate.metavivor.org/give/318818/#!… #bcsm

1/ Big moment for patient-centered dosing: A new Journal of Clinical Oncology article calls for change—and backs it with real-world data from PCDI The Right Dose 2020 survey. (Our new survey’s in progress now!) 🧵

2/ Our 2020 survey of 1,221 people with metastatic breast cancer found: • ⚠️ 86% experienced major side effects • 📉 43% had to skip treatments • ✓ 83% felt better after dose reductions • 🗣️ 92% want to talk about personalized 🧵

3/ The article aligns PCDI The Right Dose with FDA’s Project Optimus—part of a broader movement to rethink the “maximum tolerated dose” in favor of what patients can actually tolerate over time. 🧵

4/ Dosing isn’t just a science issue. It’s a quality of life issue—especially for people on treatment for the long haul. Read the article online  ascopubs.org/doi/full/10.12… #DoseOptimization #MBC #Oncology 🧵

It warms my 🫀(and frankly brings a tear to my 👁️) to see Anne Loeser’s legacy live on (and grow!!): first citation in this Journal of Clinical Oncology publication. Patient-led PCDI The Right Dose is small, but mighty. ascopubs.org/doi/10.1200/JC…

RSVP for Triage Cancer 's FREE webinar for What to do when An Insurance Company Says "No" on 8/12! Learn about the appeals process, Medicare, and Medicaid. + FREE CE for professionals. Register here: buff.ly/I6fkgaS #TriageTalks #CancerRights #InsuranceAppeals

This is where the importance of government cancer funding comes in. My brilliant colleague designing a large trial to give less trastuzumab to HER2+ patients who achieve pCR.

Ever felt like you needed a science degree just to get the right treatment? Terms like CDK4/6 inhibitors, HER2-low, and PIK3CA mutation can be overwhelming - but they’re also essential when it comes to accessing the right care. Medical jargon shouldn't be a barrier to

Registration is OPEN for Stage IV Stampede! Join us Oct. 6–7 in DC to bring metastatic breast cancer advocacy to Capitol Hill. NEW this year: $500 Travel stipend raffle! Register now: donate.metavivor.org/event/2025-sta…

Off the grid enjoying crisp mountain air, wildlife & no 📆/mtg alerts. A little adventure, a lot of nature, & just what I needed to hit pause, breathe & restore. Nature wins every time. Inbox =chaos, but soul=recharged. Self-care matters. #LiveLifeFully #Grateful

Changes in HER2low and HER2-ultralow status in 47 advanced breast carcinoma core biopsies, matching surgical specimens, and their distant metastases assessed by conventional light microscopy, digital pathology, and artificial intelligence buff.ly/vkthC7v This study

SEA TO SEA FOR MBC We’re hitting the road for #MBC! AUG: CO, KS, MO SEPT/OCT: IN, OH, PA, NY, DC Host a fundraising event & we might stop by! Form: surveymonkey.com/r/BPMDP6H More info: metavivor.org/take-action/ca…

on the road again..... Janice Cowden and I would love to see you on our first leg: 8/19 Denver U Colorado Anschutz researcher visits 8/22 Kansas City KUMC meet Dr Danny Welch, first grant recipient and Scientific Advisory Board member 8/23 St Louis meetup with area folks

Are you going to be at #SABCS25? Let’s🗣️ the current SoC & how #SABCS25 will impact this! InPerson: Dec 10, 2025 w/ Stephanie Graff, MD, FACP, FASCO Susan dent Erika Hamilton, MD, FASCO Paolo Tarantino Komal Jhaveri Kevin Kalinsky, MD, MS, FASCO Register: bit.ly/aiosabcs25 #AdvInOnc25 #OncTwitter OncoAlert

Pearls for talking to patients: 1) AI for 5 years is the goal, more has modest benefits. 2) 5 additional years reduces recurrence risk by 3-4%, most of these are new breast events 3) reduces distant recurrence by 2% (5 more years) 4) no OS benefit

Janice Cowden Stephanie Graff, MD, FACP, FASCO Susan dent Erika Hamilton, MD, FASCO Paolo Tarantino Komal Jhaveri Kevin Kalinsky, MD, MS, FASCO OncoAlert OncUpdates Sarah Premji, MD Arya Roy Nerea Lopetegui-Lia, MD Jasmin Hundal, M.D., DipABLM, M.S., M.P.H. Alexis LeVee, MD Sara Tolaney G Curigliano MD PhD Neil Iyengar, MD Thank you, Janice Cowden - would love to see you and all our other patients/patient advocates there 🙏🏽🙏🏽